CagriSema and REIMAGINE 2: what Phase 3 results mean for people with type 2 diabetes

GLP-1 receptor agonists (like semaglutide, tirzepatide, and others) are now well established in the treatment of type 2 diabetes and obesity. They work by mimicking a gut hormone that stimulates insulin secretion and reduces appetite.

Amylin is a different pancreatic hormone, co-secreted with insulin in response to eating. It slows gastric emptying, suppresses glucagon, and plays a role in appetite regulation through pathways distinct from GLP-1. Pramlintide, an older amylin analog, has been available for years — but it requires multiple daily injections and has limited clinical uptake.

Cagrilintide is a novel long-acting amylin receptor agonist designed for once-weekly dosing — a significant formulation advance. CagriSema co-formulates cagrilintide and semaglutide in a single weekly injection, with the theory that targeting both pathways will produce additive effects on glycemic control and weight.

Novo Nordisk ran three Phase 3 trials evaluating CagriSema specifically in people with type 2 diabetes.

REIMAGINE 1 (N=189, 40 weeks): Adults with T2D inadequately controlled on diet and exercise alone — essentially treatment-naive patients. CagriSema 2.4 mg/2.4 mg reduced HbA1c by 1.8 percentage points and weight by 13.8%, versus 0.1 percentage points and 1.4% for placebo.

REIMAGINE 2 (N=2,713, 68 weeks): Adults with T2D on metformin with or without an SGLT2 inhibitor. This is the trial with the active comparator (semaglutide 2.4 mg) — the one that generated the most attention at ADA 2026.

REIMAGINE 3 (N=274, 40 weeks): Adults with T2D adding CagriSema to existing basal insulin therapy. This is the add-on population — a group with more advanced disease and harder-to-control glucose.

All three trials met their primary endpoints. REIMAGINE 1 and 2 results were published simultaneously in The Lancet Diabetes and Endocrinology (PMID 42251859, 42251860). REIMAGINE 3 was published in The Lancet.

REIMAGINE 2 is the pivotal trial, because it directly compared CagriSema to semaglutide 2.4 mg in a large population over 68 weeks. The primary endpoint was change in HbA1c at 68 weeks.

Using the efficacy estimand (which models the outcome had all participants continued treatment as planned):

CagriSema 2.4 mg/2.4 mg (n=603): HbA1c change -1.91 percentage points; weight change -14.2% Semaglutide 2.4 mg (n=605): HbA1c change -1.75 percentage points; weight change -10.2%

Mean baseline HbA1c was 8.2%; mean baseline weight was 100.9 kg.

The difference in HbA1c reduction was statistically significant (p=0.0035). The difference in weight reduction was also significant (p<0.0001).

The HbA1c gap of 0.16 percentage points is real but modest — clinical practice often looks for differences in the 0.3 to 0.5 percentage-point range as a marker of meaningful clinical differentiation. The weight gap of 4 percentage points is more substantial, particularly for patients managing multiple cardiometabolic risk factors alongside blood sugar control.

What this means in practice depends on the individual. A patient who has not responded adequately to semaglutide, or for whom weight reduction is a primary clinical priority alongside glycemic control, would have a different conversation with their prescriber than someone whose HbA1c is well-controlled on semaglutide alone.

This trial compared CagriSema to semaglutide 2.4 mg — the Wegovy dose, not the lower Ozempic doses (0.5 to 1 mg) used in standard diabetes management. That is an important distinction: the comparator is already at the highest labeled semaglutide dose.

CagriSema's advantage in this trial is an additional 4 percentage points of body weight reduction and a modest incremental HbA1c improvement, on top of an already highly effective comparator.

This trial did not include tirzepatide as a comparator. Tirzepatide showed 15 to 22% body weight reduction in obesity trials depending on dose, but those are different populations (obesity without T2D) and different endpoints. Drawing direct cross-trial comparisons is not reliable without a head-to-head trial.

CagriSema is investigational. As of June 2026, Novo Nordisk has submitted an NDA for CagriSema to the FDA. The timeline for FDA's decision has not been publicly disclosed.

Until the FDA grants approval, CagriSema is not available by prescription in the United States. There is no authorized pathway to obtain it outside of a registered clinical trial.

Separate from the T2D indication tested in REIMAGINE, Novo Nordisk has also studied CagriSema in adults with obesity without T2D through the REDEFINE program. Those are different trials, a different patient population, and a separate regulatory question. REIMAGINE data (T2D) and REDEFINE data (obesity without diabetes) should not be conflated.

• FDA approval timeline for CagriSema in T2D — no public disclosure as of June 2026
• How CagriSema compares head-to-head with tirzepatide in T2D populations — no such trial has been published
• Long-term cardiovascular outcomes data for CagriSema — no dedicated CVOT has reported as of June 2026
• Safety in specific subpopulations (renal impairment, elderly, prior bariatric surgery)
• Whether the once-weekly formulation will require dose titration protocols comparable to semaglutide or tirzepatide, and what that means for tolerability

• My HbA1c is not at goal — is the REIMAGINE 2 data relevant to where I am in my treatment progression?
• How does what CagriSema offers compare to what tirzepatide offers for someone in my situation?
• If CagriSema becomes available, would I be a candidate? What would the prescribing criteria likely look like?
• Are there clinical trials for CagriSema still enrolling that I might qualify for?
• What cardiovascular outcome data would you want to see before considering this for someone with my cardiac risk profile?

The REIMAGINE trials confirm that combining amylin and GLP-1 pathways in a single weekly injection produces meaningful improvements in both glycemic control and weight in adults with type 2 diabetes. The differences over semaglutide 2.4 mg are real — particularly for weight, which showed a 4-percentage-point advantage at 68 weeks.

What the data do not yet answer is how CagriSema fits into the broader treatment hierarchy once tirzepatide and other agents are in the comparison. That question will matter more once the drug is approved and prescribers are choosing between available options.

For now, CagriSema is in the pipeline. If you have type 2 diabetes and your current treatment is not hitting your HbA1c or weight goals, the conversation to have is with your clinician — about what is currently available, and what questions to ask when CagriSema's regulatory story becomes clearer.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• REIMAGINE 2 primary publication. The Lancet Diabetes and Endocrinology. PMID 42251859. pubmed.ncbi.nlm.nih.gov
• ClinicalTrials.gov: NCT06065540. clinicaltrials.gov
• Novo Nordisk press release, June 7, 2026. prnewswire.com
• Healio Endocrine Today. CagriSema confers high magnitude of HbA1c, weight reductions in type 2 diabetes. June 8, 2026. healio.com